Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Featured Technologies

Endocytosis Routing Sequence Peptides for Cell Delivery Systems

Opportunity ContactEnikő Koppány, Business Development ManagerSzeged, Hungary University of Szeged Website Pharmalicensing.com The WYKYW pentapeptide is an endocytosis routing sequence for cell delivery of therapeutic macromolecules at therapeutically relevant nanomolar concentrations and

November 11, 2020
Read more
Strategic Partnering

Outlicensing opportunity for Proprietary Compound and Nasal Spray for the Treatment of Obesity

Both ABSOLVE and ABSCENT have been evaluated in the clinic and have been more effective / better tolerated than other obesity therapeutics.
Average weight loss is 10 lbs. during the first month’s use (observed range = 4 lbs. to 15 lbs.) and 2 lbs. to 10 lbs. per month thereafter.
ABSOLVE’s APIs are both components of other diet medicines.

August 28, 2020
Read more

2020 Cognis Group. All Rights Reserved.